MLSS · Milestone Scientific Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $598.0K | - | $719.2K | $705.9K | $585.0K | - | $677.6K | $442.6K | $572.7K | - |
| Gross Profit | $1.56M | - | $1.64M | $1.62M | $1.65M | - | $1.84M | $1.41M | $1.68M | - |
| R&D | - | - | $16.2K | $51.8K | $369.1K | - | $232.1K | $315.0K | $94.2K | - |
| SG&A | $2.37M | - | $2.74M | $3.03M | $3.26M | - | $3.06M | $2.87M | $3.04M | - |
| Total Operating Expenses | $2.39M | - | $2.78M | $3.10M | $3.65M | - | $3.31M | $3.19M | $3.14M | - |
| D&A | $19.5K | - | $20.1K | $19.5K | $19.4K | - | $8.6K | $8.5K | $11.7K | - |
| Operating Income | ($828.1K) | - | ($1.13M) | ($1.48M) | ($2.00M) | - | ($1.47M) | ($1.78M) | ($1.47M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | $0 | - | - | - | - | $0 | - |
| Net Income | ($839.9K) | - | ($1.15M) | ($1.48M) | ($1.99M) | - | ($1.46M) | $223.6K | ($1.44M) | - |
| EPS - Basic | ($0.01) | - | ($0.01) | ($0.02) | ($0.02) | - | ($0.02) | $0.00 | ($0.02) | - |
| EPS - Diluted | ($0.02) | - | ($0.02) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.20M | $1.11M | $1.35M | $1.27M | $2.25M | $3.26M | $4.78M | $5.75M | $4.01M | $2.98M |
| Accounts Receivable | - | - | - | - | - | $475.4K | $551.0K | $386.8K | $661.8K | $312.7K |
| Inventory | $3.49M | $3.78M | $4.13M | $3.90M | $4.16M | $3.71M | $3.71M | $3.33M | $2.86M | $2.64M |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $7.35M | $7.48M | $8.11M | $7.63M | $8.62M | $9.29M | $10.70M | $11.49M | $10.81M | $10.79M |
| Total Assets | $7.96M | $7.81M | $8.49M | $8.05M | $9.09M | $9.80M | $11.17M | $12.01M | $11.35M | $11.37M |
| Current Liabilities | $4.86M | $4.13M | $5.03M | $3.77M | $4.44M | $3.74M | $3.76M | $3.83M | $3.64M | $3.08M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.68M | $4.99M | $5.94M | $4.71M | $4.63M | $3.96M | $3.95M | $4.05M | $3.89M | $3.36M |
| Stockholders' Equity | $2.28M | $2.81M | $2.55M | $3.34M | $4.46M | $5.83M | $7.22M | $7.95M | $7.46M | $8.01M |
| Retained Earnings | ($134.62M) | ($133.78M) | ($132.68M) | ($131.53M) | ($130.05M) | ($128.05M) | ($126.02M) | ($124.56M) | ($124.78M) | ($123.34M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $86.8K | - | - | - | ($1.01M) | - | - | - | ($1.22M) | - |
| Investing Cash Flow | ($1.6K) | - | - | - | ($1.3K) | - | - | - | $2.00M | - |
| Financing Cash Flow | ($3.4K) | - | - | - | ($2.3K) | - | - | - | $241.4K | - |
| CapEx | $1.3K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | $85.5K | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | -0.10 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.5% | - | -13.6% | -18.4% | -21.9% | - | -13.1% | 1.9% | -12.7% | - |
| Return on equity | -36.8% | - | -45.3% | -44.4% | -44.7% | - | -20.2% | 2.8% | -19.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.51 | 1.81 | 1.61 | 2.03 | 1.94 | 2.48 | 2.85 | 3.00 | 2.97 | 3.51 |
| Quick ratio | 0.79 | 0.89 | 0.79 | 0.99 | 1.00 | 1.49 | 1.86 | 2.13 | 2.19 | 2.65 |
| Cash ratio | 0.25 | 0.27 | 0.27 | 0.34 | 0.51 | 0.87 | 1.27 | 1.50 | 1.10 | 0.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.48 | 2.78 | 3.33 | 2.41 | 2.04 | 1.68 | 1.55 | 1.51 | 1.52 | 1.42 |
| Liabilities / Assets | 0.71 | 0.64 | 0.70 | 0.59 | 0.51 | 0.40 | 0.35 | 0.34 | 0.34 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.17 | - | 0.17 | 0.18 | 0.14 | - | 0.18 | 0.13 | 0.20 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 2131d | - | 2094d | 2015d | 2595d | - | 1999d | 2746d | 1823d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 10.8x | - | 14.1x | - | - | - | - | 6.8x | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -5.1% | - | -10.6% | 14.6% | -1.7% | - | 22.1% | -25.3% | -11.3% | - |
| Operating income growth (YoY) | 58.6% | - | 22.8% | 16.6% | -36.4% | - | 2.5% | 21.8% | -9.1% | - |
| Net income growth (YoY) | 57.9% | - | 21.0% | - | -38.5% | - | 0.3% | - | -10.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -48.8% | -51.8% | -64.7% | -58.0% | -40.2% | -27.2% | -0.3% | 0.1% | -21.3% | -21.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$270.0K totalInstruments$270.0K · 100.0%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing MILESTONE SCIENTIFIC INC. against the 5 most active filers in the same SIC group.